Cargando…

Contribution of CSF biomarkers to early‐onset Alzheimer's disease and frontotemporal dementia neuroimaging signatures

Prior studies have described distinct patterns of brain gray matter and white matter alterations in Alzheimer's disease (AD) and frontotemporal lobar degeneration (FTLD), as well as differences in their cerebrospinal fluid (CSF) biomarkers profiles. We aim to investigate the relationship betwee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Falgàs, Neus, Ruiz‐Peris, Mariona, Pérez‐Millan, Agnès, Sala‐Llonch, Roser, Antonell, Anna, Balasa, Mircea, Borrego‐Écija, Sergi, Ramos‐Campoy, Oscar, Augé, Josep Maria, Castellví, Magdalena, Tort‐Merino, Adrià, Olives, Jaume, Fernández‐Villullas, Guadalupe, Blennow, Kaj, Zetterberg, Henrik, Bargalló, Núria, Lladó, Albert, Sánchez‐Valle, Raquel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267898/ https://www.ncbi.nlm.nih.gov/pubmed/31944489 http://dx.doi.org/10.1002/hbm.24925

Ejemplares similares

Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimer’s disease
por: Contador, José, et al.
Publicado: (2021)

Classifying Alzheimer's disease and frontotemporal dementia using machine learning with cross‐sectional and longitudinal magnetic resonance imaging data
por: Pérez‐Millan, Agnès, et al.
Publicado: (2023)

Early‐onset Alzheimer's disease shows a distinct neuropsychological profile and more aggressive trajectories of cognitive decline than late‐onset
por: Tort‐Merino, Adrià, et al.
Publicado: (2022)

The APOE4 effect: structural brain differences in Alzheimer's disease according to the age at symptom onset
por: Forno, Gonzalo, et al.
Publicado: (2022)

Hippocampal atrophy has limited usefulness as a diagnostic biomarker on the early onset Alzheimer's disease patients: A comparison between visual and quantitative assessment
por: Falgàs, Neus, et al.
Publicado: (2019)

Novel P397S MAPT variant associated with late onset and slow progressive frontotemporal dementia
por: Borrego‐Écija, Sergi, et al.
Publicado: (2019)

Thalamic nuclei changes in early and late onset Alzheimer's disease
por: Forno, Gonzalo, et al.
Publicado: (2023)

Serum neurofilament light levels correlate with severity measures and neurodegeneration markers in autosomal dominant Alzheimer’s disease
por: Sánchez-Valle, Raquel, et al.
Publicado: (2018)

APP‐derived peptides reflect neurodegeneration in frontotemporal dementia
por: Illán‐Gala, Ignacio, et al.
Publicado: (2019)

Sex influences clinical phenotype in frontotemporal dementia
por: Pengo, Marta, et al.
Publicado: (2022)

Prodromal frontotemporal dementia: clinical features and predictors of progression
por: Benussi, Alberto, et al.
Publicado: (2021)

Analytical and clinical validation of a blood progranulin ELISA in frontotemporal dementias
por: Meda, Francisco, et al.
Publicado: (2023)

Cognitive decline in amyotrophic lateral sclerosis: Neuropathological substrate and genetic determinants
por: Borrego‐Écija, Sergi, et al.
Publicado: (2021)

Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer’s disease and frontotemporal lobar degeneration
por: Benussi, Alberto, et al.
Publicado: (2022)

Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration
por: Illán-Gala, Ignacio, et al.
Publicado: (2021)

Synergistic Association between Plasma Aβ(1–42) and p-tau in Alzheimer’s Disease but Not in Parkinson’s Disease or Frontotemporal Dementia
por: Chiu, Ming-Jang, et al.
Publicado: (2021)

Functional networks and structural connectivity of visuospatial and visuoperceptual working memory
por: Sala-Llonch, Roser, et al.
Publicado: (2015)

Plasma neurofilament light protein correlates with diffusion tensor imaging metrics in frontotemporal dementia
por: Spotorno, Nicola, et al.
Publicado: (2020)

CSF synaptic protein concentrations are raised in those with atypical Alzheimer’s disease but not frontotemporal dementia
por: Clarke, Mica T. M., et al.
Publicado: (2019)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Endo‐lysosomal protein concentrations in CSF from patients with frontotemporal dementia caused by CHMP2B mutation
por: Toft, Anders, et al.
Publicado: (2023)

Differences and similarities between familial and sporadic frontotemporal dementia: An Italian single‐center cohort study
por: Benussi, Alberto, et al.
Publicado: (2022)

Validation of a prefractionation method followed by two-dimensional electrophoresis – Applied to cerebrospinal fluid proteins from frontotemporal dementia patients
por: Hansson, Sara Folkesson, et al.
Publicado: (2004)

Cortical microstructure in primary progressive aphasia: a multicenter study
por: Illán-Gala, Ignacio, et al.
Publicado: (2022)

Correction: Cortical microstructure in primary progressive aphasia: a multicenter study
por: Illán-Gala, Ignacio, et al.
Publicado: (2023)

Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease
por: Rosén, Christoffer, et al.
Publicado: (2014)

CSF placental growth factor – a novel candidate biomarker of frontotemporal dementia
por: Hansson, Oskar, et al.
Publicado: (2019)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010)

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders
por: Andreasson, Ulf, et al.
Publicado: (2016)

Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest
por: Foiani, Martha S, et al.
Publicado: (2019)

Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
por: Rohrer, Jonathan D., et al.
Publicado: (2016)

Cortical Thickness and Behavior Abnormalities in Children Born Preterm
por: Zubiaurre-Elorza, Leire, et al.
Publicado: (2012)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer’s disease
por: Boza-Serrano, Antonio, et al.
Publicado: (2022)

COVID-19 severity is related to poor executive function in people with post-COVID conditions
por: Ariza, Mar, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8ltfr48ag3crciadt0nm9jqi5j